Member login

By using the members area you have already agreed to share your personal information with the BGMA/BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Cookie Policy

We use cookies on our website to ensure that we give you the best experience we can. If you continue to use our site without changing your settings, we'll assume that you are happy for us to use cookies. More information can be found in our Privacy Policy.

Brexit: Response to Government update on medicines and medical products supply

Warwick Smith, Director General of the British Generic Manufacturers Association (BGMA), said: “We welcome the Government providing more information on its plans to ensure appropriate supplies of medicines are available to patients in light of a no-deal Brexit. We have been working with the authorities for many months to put these plans in place, and it is right that they are In more transparent on their plans in the interests of patients as well as the supply chain.

“While we welcome the Government’s efforts to help ensure that patients continue to receive their medicines in the case of a no deal Brexit, we are absolutely clear that the only way to ensure continued availability of medicines, and future launches, is to be part of European Union regulatory framework and single market. We must avoid different standards and any checks at the border otherwise there will be an inevitable impact on patient well-being.”